PharmScript LLC

pharmscript.com

As a leading pharmacy provider to long-term care and post-acute care facilities, PharmScript partners with healthcare organizations across 10 states, and delivers medications to thousands of residents and patients. Founded in 2009 with the goal of providing a seamless pharmacy experience, PharmScript is committed to helping providers deliver patient-centered care with high quality service, accuracy, timeliness, and cost containment

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

news image

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

news image

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More

Business Insights

LOUIS DRAPEAU HAS RESIGNED FROM THE BOARD OF DIRECTORS OF AVITA MEDICAL, INC

AVITA Medical | April 22, 2022

news image

Louis Drapeau has resigned from the Board of Directors of AVITA Medical, Inc. a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, effective April 29, 2022. Mr. Drapeau's resignation is not the result of a disagreement with the Company over any of its operations, policies, or procedures. Rather, he is stepping down for personal reasons. Since January 2016, M...

Read More

Research

HEMOGENYX PHARMACEUTICALS AND SELEXIS SA WILL ADVANCE HEMOGENYX’S ACUTE MYELOID LEUKEMIA (AML) CDX BISPECIFIC ANTIBODY TO HUMAN TRIALS

Hemogenyx Pharmaceuticals plc | January 13, 2022

news image

Hemogenyx Pharmaceuticals plc the biopharmaceutical group developing new therapies and treatments for blood diseases, and Selexis SA, a JSR Life Sciences company, have signed a service agreement to develop the cell line for Hemogenyx’s CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly redu...

Read More
news image

PHARMA TECH

AION LABS WELCOMES AMITI AS STRATEGIC PARTNER TO ACCELERATE ISRAEL'S POSITION AS A LEADING HUB FOR TRANSFORMATIVE AI-POWERED DRUG DISCOVERY INNOVATION

PR Newswire | January 09, 2024

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups. "With a pr...

Read More
news image

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More
news image

Business Insights

LOUIS DRAPEAU HAS RESIGNED FROM THE BOARD OF DIRECTORS OF AVITA MEDICAL, INC

AVITA Medical | April 22, 2022

Louis Drapeau has resigned from the Board of Directors of AVITA Medical, Inc. a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, effective April 29, 2022. Mr. Drapeau's resignation is not the result of a disagreement with the Company over any of its operations, policies, or procedures. Rather, he is stepping down for personal reasons. Since January 2016, M...

Read More
news image

Research

HEMOGENYX PHARMACEUTICALS AND SELEXIS SA WILL ADVANCE HEMOGENYX’S ACUTE MYELOID LEUKEMIA (AML) CDX BISPECIFIC ANTIBODY TO HUMAN TRIALS

Hemogenyx Pharmaceuticals plc | January 13, 2022

Hemogenyx Pharmaceuticals plc the biopharmaceutical group developing new therapies and treatments for blood diseases, and Selexis SA, a JSR Life Sciences company, have signed a service agreement to develop the cell line for Hemogenyx’s CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly redu...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us